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ABSTRACT 
 
Introduction: The management of pelvic organ prolapse (POP) varies significantly between 
countries. The objective of this study was to describe the methods used for POP surgery in 
Finland and to identify the factors that affect clinicians’ choice to use either a native tissue 
repair (NTR) or mesh repair method. Material and Methods: This prospective cohort study 
included 3,535 surgeries covering 83% of all POP operations performed in Finland in 2015. 
The operative details and patient characteristics, including the Pelvic Floor Distress Inventory 
(PFDI-20), were compared between three selected surgical methods (NTR, transvaginal mesh 
(TVM), and abdominal mesh (AM)). The predictive factors for the use of mesh augmentation 
were also studied with logistic regression analysis. Results: The most common method was 
NTR (N=2855, 81%), followed by TVM (N=429, 12%) and AM (N=251, 7%). 
Approximately 92% of patients who underwent primary prolapse surgery underwent NTR, 
and mesh surgery was used mainly for recurrent prolapse. The strongest predictor of mesh 
surgery was previous POP surgery for the same vaginal compartment (adjusted odds ratio 
(OR) = 56, 95% confidence interval (CI) = 38-84 for TVM; adjusted OR = 22, 95% CI = 14-
34 for AM). Other predictive factors for mesh surgery were previous hysterectomy, 
healthcare district, severe bulge symptoms and advanced prolapse. TVM was associated with 
advanced anterior prolapse and older age. AM surgery was associated with advanced apical 
and/or posterior compartment prolapse. PFDI-20 scores were the highest in the AM group 
(108 vs 103 in the TVM group and 98 in the NTR group, p=0.012), which indicates more 
bothersome symptoms than in the other groups. Conclusions: The Finnish practices follow 
international guidelines that advocate NTR as the principal surgical method for POP. 
Synthetic mesh augmentation was mainly used in patients with recurrent and advanced 
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prolapse with severe symptoms. The variation in the rates of mesh augmentation for POP 
surgery in different hospitals implies a lack of sufficient evidence of the most suitable 
treatment method and indicates a need for national guidelines. 
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ABBREVIATIONS 
POP, pelvic organ prolapse;  
NTR, native tissue repair;  
TVM, transvaginal mesh;  
AM, abdominal mesh;  
PFDI, Pelvic Floor Distress Inventory;  
OECD, Organisation for Economic Co-operation and Development 
 
Key message 
In Finland, pelvic organ prolapse is repaired vaginally with native tissue in eight out of ten 
surgeries. Mesh surgery is used mainly for recurrent prolapse and for patients with advanced 
prolapse and bothersome symptoms. 
 
1. INTRODUCTION 
 
More than one in ten women undergoes pelvic organ prolapse (POP) surgery in their 
lifetime.
1, 2
 In Finland, the lifetime likelihood of POP surgery is 13%, and approximately 
4,200 operations are performed annually.
3, 4
 There are numerous different methods for POP 
surgery.
5
 Clinicians must choose between vaginal and abdominal surgical approaches, decide 
whether to use native tissue or a surgical mesh, choose to repair one or multiple sites of 
prolapse, and decide whether concomitant surgery, such as hysterectomy or incontinence 
surgery, is necessary. The operative method depends on the nature, site and severity of the 
prolapse and the symptoms affecting urinary, bowel or sexual function.
6
 The patient’s general 
health and individual needs and values should be considered when determining the operative 
method.
7, 8
 
There continues to be a limited level of evidence to guide clinicians in choosing the 
best surgical technique for a particular patient.
7
 Furthermore, a surgeon’s own preferences 
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and capabilities influence the decision. There is significant heterogeneity (>10-fold) in the 
rates at which individual POP procedures are performed in different countries.
9 
Recently, the 
risks related to mesh augmentation have caused debate regarding the safety of this method for 
POP surgery.
10 
Thus, different surgical techniques and their safety and effectiveness requires 
further assessment.
 
This nationwide prospective annual cohort study reports the methods used for POP 
surgery in Finland in 2015. The patient characteristics and symptoms were compared 
between women who were treated with native tissue repair (NTR), a vaginal mesh or an 
abdominal mesh (AM) augmentation to identify the factors that affect clinicians’ choice to 
use a mesh instead of NTR for POP surgery. 
 
2. MATERIAL AND METHODS 
 
All Finnish hospitals that performed POP surgery in 2015 were invited to participate 
in this nationwide prospective multicenter study. The study was organized by the Finnish 
Society for Gynecological Surgery, and the study protocol of a national multicenter study 
with local doctors in charge was similar to a previous study of hysterectomies (FINHYST 
2006).
11
 The study period was between 1.1.2015 and 31.12.2015. We retrieved the actual 
total number of POP operations performed in Finland during this period from the Finnish 
Hospital Discharge Register of the National Institute for Health and Welfare.
4
 The inclusion 
criteria for the patients were age older than 18 years old and ability to communicate in written 
and oral Finnish or Swedish. Written informed consent was obtained from each patient. 
The surgical treatment and patient characteristics were derived from questionnaires 
filled out by both doctors and patients. The usefulness and reliability of the questionnaires 
(paper and electronic forms) and the study protocol were tested in a pilot study performed in 
2014 at Tampere University Hospital, Central Finland Central Hospital and Kanta-Häme 
Central Hospital. The data from the pilot study are not included in this analysis. 
The surgeons completed an electronic study questionnaire. The degree of prolapse 
was assessed using a simplified Pelvic Organ Prolapse Quantification (POPQ) system.
6
 The 
surgeons recorded the single most distal Pelvic Organ Prolapse Quantification point of all 
three compartments of the vagina (anterior, posterior or apical) in centimeters from the 
hymen. They also documented the operative method with a description and a code from the 
Nordic Classification of Surgical Procedures (NCSP). 
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The participants completed a questionnaire either as an electronic or paper form based 
on their own preferences. They reported their worst symptoms related to pelvic floor 
dysfunction, such as an awareness of a bulge or a feeling of pelvic pressure, urinary or 
defecation problems, pain, or other symptoms. They also reported their height (cm), weight 
(kg), chronic diseases, medication, parity, mode of delivery, and smoking status. We 
administered validated health-related quality of life questionnaires either in Finnish
12
 or 
Swedish
13
 and the short version of the Pelvic Floor Distress Inventory (PFDI-20),
14
 which 
measures the severity of POP symptoms. The questionnaires were collected separately by the 
investigators and were not available to the surgeons. The surgical method was determined by 
the individual surgeon’s preference based on clinical judgment. 
 
2.1. Statistical analyses 
The operations were categorized into three groups: NTR, transvaginal mesh 
augmentation (TVM), and abdominal mesh (AM) augmentation. Patient characteristics and 
surgical details were analyzed in the whole study population and in each surgical method 
group. The statistical significance was set at P<0.05. The differences in categorical variables 
between the surgery groups were tested with the χ2 test. Q-Q-plots were used to assess the 
distribution of continuous variables, and Levene’s test was used to assess the equality of 
variances in the different groups. When the variances were equal, the differences among 
continuous variables between the groups were tested with an analysis of the variance, and the 
Bonferroni method was applied to assess pairwise comparisons. For variables with unequal 
variance, the Brown-Forsythe test was used to assess the differences between the groups, and 
Dunnett's T3 was used to assess pairwise differences. Binary logistic regression was used to 
identify the predictors for the use of a vaginal mesh or an AM. The results were adjusted for 
age, sexual activity, previous hysterectomy or POP surgery, degree of bulge symptoms, 
health care district and type of hospital. There were no indications for collinearity between 
the factors included in the model (all correlation coefficients<0.4). All statistical calculations 
were performed with SPSS 24.0 (IBM Corp., Armonk, NY, USA). 
 
2.2. Ethical approval 
The Research Ethics Committee of the Northern Savo Hospital District approved the 
protocol (Reference number 5//2014). Approval was also obtained from the Finnish Ministry 
of Social Affairs and Health and from the institutional review boards of each participating 
hospital. The study was included in the ClinicalTrials.gov protocol registration system 
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(NCT02716506) and followed the ethical standards for human experimentation established 
by the Declaration of Helsinki of 1964, revised in 2013.
15
 
 
3. RESULTS 
 
Forty-one of the 45 (91%) hospitals performing POP surgeries in Finland participated: 
all five Finnish university hospitals, 17/18 secondary hospitals, 15/17 primary hospitals and 
4/5 private clinics. Of the 3,535 operations included in the study, 1,169 (33%) were 
performed in tertiary, 1,562 (44%) in secondary, and 745 (21%) in primary hospitals, and 44 
(1.3%) in private clinics. The participation rate varied between centers and was 42–100% 
(Supporting Information Appendix S1). The flow chart of participant enrollment and the data 
availability are presented in Figure 1. In 2015, altogether 4,240 POP operations were 
performed in Finland, corresponding to a rate of 1.52 per 1,000 women. The study population 
(N=3515 patients, 3535 operations) covered 83% of all women that underwent surgery for 
POP in Finland in the 2015. Approximately 83% (N=2903) of the participants completed all 
the preoperative questionnaires including the PFDI-20 questionnaire. 
The patient characteristics are depicted in Table 1. The patients who underwent TVM 
were significantly older, less sexually active, and more likely to have cardiovascular diseases 
or be treated with medication for chronic disease than patients in the other groups. There was 
no significant difference in the proportion of obese patients between the groups. The 
participants’ smoking habits and parity did not differ between groups. Altogether, 1,701 
(48%) patients had a history of previous pelvic surgery. The total previous hysterectomy rate 
was 79% for the TVM, 76% for the AM and 23% for the NTR groups (P<0.001). A total of 
891 (25%) patients had undergone previous surgery for POP, and all these patients were 
symptomatic. Prolapse of the anterior compartment of the vagina was the most common form 
of prolapse. More than one compartment of the vagina was reconstructed in 1,460 (41%) of 
the operations. 
Awareness of a bulge that was reported by 93% of the patients (PFDI-20 question 
number 3). The patients’ assessment of the worst symptom related to their pelvic floor 
dysfunction was as follows: feeling of a bulge or pressure (2,003, 69%), urinary symptoms 
(468, 16%), defecation symptoms (297, 10%) and feeling of pain (60, 2%). The total PFDI-
20 scores and subscales in the three surgical groups are shown in Table 2. The highest total 
PFDI-20 scores were observed in the mesh groups, indicating greater distress due to 
symptoms; in the AM group, the average score was ten points (95% confidence interval (CI) 
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= 0.3-20, P=0.041) higher than that in the NTR group. The prolapse symptom (Pelvic Organ; 
Prolapse Distress Inventory (POPDI-6)) scores were also higher in the mesh groups. Urinary 
symptoms were significantly more common in the TVM group than in the other groups. 
Colorectal symptom scores (Colorectal-Anal Distress Inventory (CRADI-8)) were similar 
between the groups.        
The types of operations performed are summarized in Figure 2. The most common 
method of surgery – vaginal hysterectomy and colporrhaphy – was performed in 1,153 (33%) 
operations. Colporrhaphy without hysterectomy was performed in 1,308 (37%) operations, 
and isolated posterior colporrhaphy was the most common technique (n=600). Isolated 
anterior colporrhaphy was performed in 484 operations, and both anterior and posterior 
colporrhaphy were performed in 224 operations. Isolated vaginal vault repair with native 
tissue was rare (N=157, 4%), and 118 operations included hysterectomy alone. The 
Manchester operation was performed for 37 patients, and obliterative surgery (such as 
colpocleisis and vaginal closure) was performed for 29 (0.8%) patients. More detailed figures 
of the native tissue surgical procedures are available in Supporting Information Appendix S2. 
The mesh surgeries were performed in 30 out of 41 hospitals, and the number of mesh 
surgeries that were included in the study varied from 4 to 107 per center (Appendix S1). A 
transvaginal mesh was used in 429 operations, which corresponds to 0.15 per 1,000 women, 
and the most common method was anterior/apical mesh augmentation (n=361, 84%). The 
TVM kits used during surgery are summarized in Supporting Information Appendix S3. An 
AM augmentation – sacrocolpopexy – was performed in 251 operations, and 91% of those 
were performed laparoscopically.  
The factors affecting the use of a mesh are described in Table 3. The strongest 
predictor for the use of a mesh was a previous POP surgery of the same vaginal compartment 
(OR 56 for TVM and 22 for AM).  Other predictive factors were previous hysterectomy and 
severe bulge symptoms. TVM was associated with advanced anterior prolapse, whereas AM 
augmentation was associated with advanced apical and posterior prolapse. Regional 
differences in practices were found. The patient’s healthcare district was a strong predictor of 
the use of mesh surgery; there was almost a 10-fold difference between the highest and 
lowest odds ratio (OR) for the use of a transvaginal mesh. The hospital level did not explain 
the variation in the use of a mesh. 
A total of 2,644 (75%) operations were performed for patients without prior prolapse 
surgery, and 92% of these were performed using native tissue. A total of 206 (8%) 
participants received a mesh for primary prolapse, 103 received TVM, and 103 received AM. 
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The type of hospital did not affect the risk of primary TVM, but there was significant 
variation in the practices between hospitals (Supporting Information Appendix S1). Risk 
factors for TVM as the primary surgery were advanced anterior or apical prolapse, 
bothersome bulge symptoms, and healthcare district (Table 3). An AM augmentation was 
used as the primary surgery more often for patients with rectal intussusception (OR = 20.1, 
95% CI = 12.9–31.6), and other predictive factors were advanced apical or posterior 
compartment prolapse. Previous hysterectomy was a risk factor for both transvaginal mesh 
and AM use during the primary surgeries. 
 
4. DISCUSSION 
 
This nationwide prospective cohort study of 3,535 operations showed that 81% of all 
patients and 92% of patients without prior prolapse surgery underwent vaginal native tissue 
reconstruction. The strongest predictors for the use of a mesh were recurrent POP, previous 
hysterectomy, healthcare district and severe bulge symptoms. TVM was associated with 
advanced anterior prolapse and older age. AM augmentation surgery was associated with 
advanced apical and/or posterior compartment prolapse and the highest total PFDI-20 scores 
indicating more bothersome symptoms than in the other groups. The median preoperative 
symptom scores were at the same level as in studies with selected patient groups, suggesting 
that the indications for POP surgery in Finland are comparable to those discussed in other 
reports.
15, 16 
The overall rate of POP surgery in Finland in 2015 was 1.5 per 1,000 women, which 
is comparable to the results a study of 15 other Organisation for Economic Co-operation and 
Development (OECD) countries in 2012.
9
 The data from other Nordic countries showed that 
the rate of POP surgery per 1,000 women was 2.0 in Sweden and 1.8 in Denmark in 2012.
9
 
The rate of TVM was 0.19, and that of AM augmentation was 0.048 per 1,000 women in 
OECD countries,
9
 while in the present study, the rates were 0.15 and 0.090 per 1,000 women, 
respectively. This finding indicates that transvaginal mesh augmentation was used 
moderately in Finland during the study period. In comparison, in 2012, the rate of TVM per 
1,000 women was 0.37 in Sweden and 0.07 in Denmark, which was reasonably higher in 
Sweden and lower in Denmark than the rate in the present study. Furthermore, the rate of 
sacral colpopexy per 1,000 women was 0.015 in Sweden and 0.006 in Denmark, which were 
both much lower figures than in Finland.
9
 Unlike in Denmark, mesh augmentations are not 
centralized in Finland and Sweden, which may partly explain the higher mesh surgery rates 
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than in Denmark. However, regional differences in POP surgical methods in Nordic countries 
have not been reported previously. We observed significant regional variation in the use of 
mesh augmentation. For transvaginal mesh surgery, this variation was almost 10-fold. This 
finding may be partly due to differences in the population, but it does imply different 
practices between hospitals. According to recent European recommendations, mesh 
augmentations should be restricted to those surgeons with appropriate training who are 
working in multidisciplinary referral centers.
17
 
Recurrence of prolapse is common. Over one to three years of follow-up after NTR, 
38% of the patients had a recurrent prolapse on examination, and 19% were aware of this 
prolapse.
18
 In the present study, 25% of the patients had underwent previous surgery for POP, 
and 17% of the patients had a recurrence in the same vaginal compartment. This finding 
suggests a moderate recurrence rate after POP surgery in Finland. Relatively few Manchester 
and obliterative procedures compared to vaginal hysterectomies were performed. In a Danish 
cohort study, vaginal hysterectomy was associated with a higher recurrence rate than the 
Manchester procedure, and this method of apical prolapse surgery should be considered if 
there is no indication for hysterectomy.
19
 
The indications for the use of a mesh during POP surgery have been widely debated 
after the Food and Drug Administration (FDA) of the United States provided second warning 
on the adverse effects of TVM surgery in 2011.
10
 The rate of TVM surgery has diminished 
dramatically,
20,21
 and in some countries, transvaginal mesh use has been abandoned.
22
 After 
the 2015 study period, most commercial transvaginal mesh kits were withdrawn from the 
market, and the rate of TVM surgery diminished in Finland.
4
 Nevertheless, after critical 
evaluation and based on patient information, transvaginal mesh augmentation remains an 
option for patients with a high risk of prolapse recurrence.
8, 18
 In randomized studies, vaginal 
mesh augmentation has provided anatomic benefits and decreased prolapse awareness and is 
associated with higher rates of de novo stress urinary incontinence, bladder injury and 
reoperations than NTR.
18, 23
 Eight percent of patients require repeat surgery due to 
transvaginal mesh exposure.
18
 Abdominal sacrocolpopexy is associated with lower risks of 
prolapse awareness and recurrence, postoperative stress urinary incontinence and dyspareunia 
than a variety of other vaginal interventions for apical prolapse.
7
 
In the present study, a recurrent POP in the same vaginal compartment was the 
strongest predictive factor for the use of a mesh. This finding is in line with recent 
recommendations.
8, 17
 For primary prolapse, the use of a synthetic mesh is controversial, and 
studies do not support using TVM in anterior or posterior compartment repair.
24 
In a Scottish 
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retrospective cohort study of 18,986 women, 7% of the primary operations were mesh 
surgeries.
25
 In our study, a similar number of primary POP operations were mesh operations. 
Posterior compartment prolapse was a protective factor for TVM, and this finding is in line 
with recommendations to avoid the use of a mesh with these patients.
8
 Advanced anterior 
prolapse is more prevalent and more prone to failure after repairs; thus, synthetic mesh may 
be beneficial.
8
 In the present study, advanced anterior prolapse was a predictive factor for 
TVM. Advanced apical and posterior compartment prolapse and rectal intussusception were 
predictive factors for AM augmentation, also in accordance with the recommendations.
7
 
Previous hysterectomy was a strong predictive factor for mesh augmentation. This finding is 
in line with those of previous studies supporting the assumption that hysterectomy increases 
the risk of later POP surgery, especially posterior compartment prolapse repair.
26, 27
 
Our study has some limitations. The participation rate varied between hospitals, 
which may bias the comparison of treatment practices between hospitals. We did not record 
the socioeconomic or menopausal statuses of the patients. The surgical method was based on 
an individual surgeon’s assessment and preferences, and the surgeons were not aware of the 
symptom scores reported on the forms completed by the patients, which may be a limitation 
but, on the other hand, reflects normal practice. Notably, 3% of patients underwent vaginal 
hysterectomy alone. This finding may be due to a coding error or a practice pattern, but 
because of the nature of the study, we could not make any further conclusions on how vaginal 
cuff suspension was performed in these cases. 
The strength of our study is that this nationwide prospective cohort covered the 
majority of all POP operations performed in Finland, offering a holistic picture of practices 
within a country. The study protocol also included clinicians’ assessments of the preoperative 
situation and validated health-related quality of life questionnaires. The previous large cohort 
studies were mainly based on retrospective databases with no symptom questionnaires 
used.
25, 28
 
 
5. CONCLUSION 
 
The practices reported here follow international recommendations that consider NTR 
to be the principal surgical method for POP surgery.
17, 18
 A synthetic mesh was mainly used 
in complex cases with recurrent prolapse in the same compartment. However, there was 
regional variation between the rates of mesh augmentation for POP surgery. In our opinion, 
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this implies a general lack of sufficient evidence regarding the most suitable treatment 
methods for POP and indicates a need for national guidelines.
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Supporting Information legends: 
 
Appendix S1. Participating hospitals and number of POP surgeries that were included in the study. 
 
Appendix S2. Surgical methods of 2855 operations performed by native tissue reconstruction. 
 
Appendix S3. Name, number and type of vaginal suspension of the used transvaginal mesh kits. 
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Table and figure legends 
 
Table 1. Patient characteristics 
 
 
Table 2. Preoperative symptom scores from Pelvic Floor Distress Inventory (PFDI-20) with 20 questions. 
Higher scores indicate greater symptom distress. 
 
Table 3. Factors affecting the use of mesh, compared to native tissue repair group. Adjusted for the confounding 
factors including age, sexual activity, previous hysterectomy, previous POP surgery, bulge symptom degree, 
health distinct area and type of hospital. 
 
Figure 1. Flow diagram of enrollment and analysis of the study participants. 
 
Figure 2. Surgical methods of operations for POP included in the study. *Native tissue repair methods are 
described in Supporting Information Appendix S2. 
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Table 1. Patient characteristics 
 
 
Characteristic 
All  
(N = 3515) 
NTR  
(N = 2850) 
TVM  
(N = 421) 
AM  
(N = 244) 
P*  
Data 
available, N (%) 
Age at operation (years) (mean ± SD) 64.0 ± 10.7 63.3 ± 11.0 68.5 ± 7.7 63.9 ± 10.0 < 0.001 3512 (100) 
Min - max (years) 26.1 - 91.7 26.1 - 91.7 48.1 - 89.3 34.4 - 85.7     
< 50 y, n (%) 361 (10.3) 340 (11.9) 2 (0.5) 169 (6.9) <0.001   
50 - 64 y, n (%) 1403 (39.9) 1169 (41.0) 131 (31.1) 103 (42.2) <0.001   
65 - 79 y, (%) 1556 (44.3) 976 (41.4) 257 (61.0) 111 (45.5) <0.001   
≥ 80 y, n (%)  192 (5.5) 150 (5.3) 31 (7.4) 11 (4.5) 0.076   
BMI (kg/m
2
) (mean ± SD) 26.9 ± 4.1 26.9 ± 4.1 27.0 ± 3.8 26.1 ± 3.7 0.022 2825 (80.4) 
Min - max (kg/m
2
) 16.0 - 59.5 16.0 - 59.5 18.3 - 42.5 16.9 - 36.9     
BMI <25, n (%) 1010 (35.7) 813 (35.7) 112 (32.1) 85 (40.7) 0.121   
BMI 25-29.9, n (%) 1252 (44.3) 994 (43.7) 167 (47.9) 91 (43.5) 0.336   
BMI ≥ 30, n (%) 572 (20.2) 469 (20.1) 70 (20.1) 33 (15.8) 0.251   
Current smokers, n (%) 252 (8.7) 206 (8.7) 28 (7.9) 21 (9.9) 0.626 2913 (82.9) 
Parity (mean ± SD) 2.55 ± 1.4 2.60 ± 1.5 2.30 ± 1.1 2.45 ± 1.4 0.122 2924 (83.2) 
Min – max 0 - 16 0 - 16 0 - 8 0 - 11     
Vaginal deliveries, median (min – 
max) 
2 (0 - 14) 2 (0 - 14) 2 (0 - 6) 2 (0 - 10) 0.666   
Caesarean sections, median (min – 
max)  
0 (0 - 4) 0 (0 - 4) 0 (0 - 4) 0 (0 - 3) 0.830   
No deliveries, n (%) 13 (0.4) 11 (0.5) 0 (0) 2 (0.9) 0.566   
Medical history           2924 (83.2) 
Cardiovascular disease, n (%) 1257 (43.0) 995 (42.3) 181 (50.7) 81 (37.2) 0.004   
Diabetes mellitus, n (%) 286 (9.8) 226 (9.6) 35 (9.8) 25 (11.8) 0.589   
Respiratory disease, n (%) 321 (11.0) 256 (10.9) 46 (12.9) 19 (9.0) 0.327   
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Medication           2924 (83.2) 
Medication for chronic disease, n 
(%) 
2022 (69.1) 1600 (67.9) 273 (76.5) 149 (70.3) 0.004   
Anticoagulative medication, n (%) 309 (10.6) 246 (10.5) 43 (12.0) 20 (9.4) 0.564   
Hormone replacement therapy, n 
(%) 
535 (18.3) 405 (17.2) 84 (23.5) 46 (21.7) 0.007   
Local estrogen therapy, n (%) 605 (20.7) 480 (20.4) 80 (22.4) 45 (21.2) 0.668   
Sexually active, n (%) 1054 (39.1) 877 (40.2) 93 (28.8) 82 (42.2) <0.001 2698 (76.7) 
Previous surgery 
 
          3515 (100) 
POP surgery, n (%) 872 (24.8) 412 (14.4) 318 (77.2) 142 (58.2) <0.001   
Same compartment operated 
previously, n (%) 
604 (17.2) 200 (7.0) 287 (68.2) 117 (48.0) < 0.001   
Different compartment operated 
previously, n (%) 
268 (7.6) 212 (7.4) 31 (7.4) 25 (10.2) 0.245   
Urinary incontinence surgery, n 
(%) 
199 (5.7) 142 (5.0) 35 (8.3) 22 (9.0) 0.001   
Hysterectomy, n (%)  1170 (33.3)  654 (22.9) 332 (78.9) 184 (75.4) <0.001   
Prolapse beyond the hymen       
Anterior vaginal wall  
(POPQ Aa or Ba>0), n (%) 
1731 (50.6) 1312 (47.7) 315 (73.8) 104 (42.2) < 0.001 3420 (97.3) 
Posterior vaginal wall  
(POPQ Ap or Bp >0), n (%) 
985 (28.9) 791 (28.9) 83 (19.6) 111 (44.8) < 0.001 3409 (97.0) 
Apex of the vagina  
(POPQ C>0), n (%) 
843 (25.9) 627 (32.2) 80 (18.8) 136 (54.4) < 0.001 3374 (96.0) 
At least one of these > 0, n (%) 2717 (79.0) 2121 (76.7) 376 (88.3) 220 (88.4) < 0.001 3441 (98.0) 
Vaginal compartment of current 
surgery 
     3515 (100) 
Anterior only, n (%) 655 (18.5) 554 (19.4) 101 (23.5) 0 (0) < 0.001  
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Apical only, n (%) 242 (6.8) 154 (5.4) 12 (2.8) 76 (30.4) < 0.001  
Posterior only, n (%) 728 (20.6) 686 (24.0) 27 (6.3) 15 (6.0) < 0.001  
Anterior and posterior, n (%) 282 (8.0) 268 (9.4) 12 (2.8) 2 (0.8) < 0.001  
Apical and anterior, n (%) 778 (22.0) 574 (20.1) 170 (39.6) 34 (13.6) < 0.001  
Apical and posterior, n (%) 175 (5.0) 97 (3.4) 30 (7.0) 48 (19.2) < 0.001  
All three compartments, n (%) 673 (19.0) 521 (18.3) 77 (17.9) 75 (30.0) < 0.001  
 
 
*P-value was calculated for the difference between the surgical method groups (NTR, TVM, AM). 
 
NTR, native tissue repair; TVM, transvaginal mesh; AM, abdominal mesh; BMI, body mass index.  
POPQ, Pelvic Organ Prolapse Quantification System; Aa, Anterior point of vaginal wall 3 cm proximal to the external urethral meatus; Ba, most 
distal point of any part of the anterior vaginal wall from vaginal cuff to point Aa; Ap, a point located in the midline of the posterior vaginal wall 
3 cm proximal to the hymen; Bp, a point that represents the most distal part of posterior vaginal wall from vaginal cuff to point Ap.  
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Table 2. Preoperative symptom scores from Pelvic Floor Distress Inventory (PFDI-20) with 20 questions. Higher scores indicate greater 
symptom distress. 
 
SYMPTOM Scores 
All  
(N = 2903) 
NTR  
(N = 2335) 
TVM  
(N = 359) 
AM  
(N = 209) 
P*  
POPDI-6, mean (95%CI) 40.9 (40.1 – 41.6) 40.2 (39.4 – 41.0) 42.7 (40.6 – 44.7) 45.5 (42.5 – 48.5) < 0.001 
CRADI-8, mean (95%CI) 26.4 (25.7 – 27.1) 26.4 (25.6 – 27.2) 24.5 (22.7 – 26.4) 29.8 (26.8 – 32.9) 0.054 
UDI-6, mean (95%CI) 32.4 (31.6 – 33.2) 
 
31.8 (31.0 – 32.7) 35.9 (33.8 – 38.0) 33.1 (30.0 – 36.1) 0.003 
Total PFDI-20 Scores, mean (95%CI) 99.7 (97.9 – 101.5) 98.4 (96.4 – 100.3) 103.1 (98.3 – 108.0) 108.4 (100.7 – 116.1) 0.012 
 
* Data was derived from questionnaires filled in for analysis of PFDI-20 scores (n=2903).  
† P-value was for the difference between the three different surgical modalities (NTR, native tissue repair; TVM, transvaginal mesh; AM, 
abdominal mesh).  
POPDI-6, Pelvic Organ Prolapse Distress Inventory of six questions about the inconvenience of the prolapse; CRADI-8, Colorectal-Anal 
Distress Inventory with eight questions concerning difficulties of defecation; UDI-6, Urinary Distress Inventory with six questions about 
difficulties in urination 
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Table 3. Factors affecting the use of mesh, compared to native tissue repair group. 
Adjusted for the confounding factors including age, sexual activity, previous hysterectomy, previous POP surgery, bulge symptom degree, health 
distinct area and type of hospital. 
Characteristic 
Transvaginal mesh 
OR (95%CI) adjusted, p 
Abdominal mesh 
OR (95%CI) adjusted, p 
All operations Primary operations All operations Primary operations 
Age at operation (years)     
< 50 y, n (%) 0.07 (0.02-0.29) 0.11 (0.03-0.46) 1.10 (0.57-2.13) 0.66 (0.28-1.41) 
50 - 64 y, n (%) 0.70 (0.49-0.99) 0.68 (0.50-0.93) 1.16 (0.78-1.71) 0.67 (0.29-1.59) 
65 - 79 y, (%) 1.00 (reference), <0.001 1.00 (reference), 0.002 1.00 (reference), 0.484 1.00 (reference), 0.708 
≥ 80 y, n (%)  0.35 (0.16-0.77) 0.60 (0.30-1.20) 0.54 (0.20-1.41) 0.86 (0.17-4.42) 
Sexual activity     
No  1.00 (reference), 0.175 1.00 (reference), 0.519 1.00 (reference), 0.249 1.00 (reference), 0.065 
Yes 0.78 (0.54-1.12) 0.90 (0.66-1.23) 1.25 (0.86-1.81) 1.64 (0.97-2.77) 
Previous surgery 
 
    
No previous POP surgery 1.00 (reference), <0.001  1.00 (reference), <0.001  
Previous POP surgery     
- same compartment 56.31 (37.86-83.74)  22.19 (14.48-34.02)  
- different compartment 2.60 (1.53-4.43)  3.05 (1.76-5.28)  
- both same and different compartment 18.82 (9.60-36.90)  14.75 (7.30-29.79)  
No hysterectomy 1.00 (reference), <0.001 1.00 (reference), <0.001 1.00 (reference), <0.001 1.00 (reference), <0.001 
Previous hysterectomy  12.97 (9.47-17.75) 12.93 (9.44-17.70) 14.61 (9.67-20.74) 6.22 (3.71-10.44) 
Prolapse beyond the hymen     
Anterior vaginal wall (POPQ Aa or Ba>0) 2.89 (2.09-4.25), <0.001 3.75 (2.72-5.16), <0.001 0.78 (0.54-1.12), 0.173 0.87 (0.52-1.46), 0.600 
Posterior vaginal wall (POPQ Ap or Bp >0) 0.56 (0.38-0.84), 0.004 0.42 (0.30-0.59), <0.001 1.97 (1.38-2.82), <0.001 1.74 (1.06-2.87), 0.030 
Apex of the vagina (POPQ C>0) 1.03 (0.68-1.56), 0.884 1.58 (1.07-2.31), 0.020 4.19 (2.90-6.05), <0.001 4.32 (2.48-7.53), <0.001 
At least one of these > 0 2.52 (1.58-4.01), <0.001 2.37 (1.58-3.56), <0.001 2.52 (1.49-4.26), 0.001 1.60 (0.80-3.20), 0.182 
Prolapse symptom (bulge)     
No 1.00 (reference), 0.007 1.00 (reference), 0.017 1.00 (reference), 0.001 1.00 (reference), 0.013 
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All surgical operations for POP in Finland from January 
1st to December 31st in 2015 
(N=4240) 
Excluded:  
Patients that id not 
participate (n=705) 
Operations for POP included in the study (n=3535) 
- 20 patients were operated twice during the study period 
ANALYSIS of operative details 
(n=3535 operations, 3515 patients)  
Excluded:  
Patients that did not fill in 
the preoperative 
questionnaires (n=592) 
Patients that filled in the preoperative questionnaires 
(n=2924)  
ANALYSIS of patient characteristics 
and preoperative symptoms 
(n= 2924) 
 Figure 1. Flow diagram of enrollment and analysis of the study participants. 
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N = 3535 
Operations for POP
Native tissue repair* 
N = 2855 (81 %)
Vaginal surgery
N = 2816 (98,6%)
Abdominal surgery
N = 13 (0,5%)
Combined surgery
N = 26 (0,9%)
Mesh 
Augmentation
N= 680 (19%)
Vaginal mesh 
augmentation 
N = 429 (63%)
Anterior / apical 
vaginal mesh
N = 361 (84%)
Posterior vaginal 
mesh N = 60  
(14%)
Total vaginal mesh
N = 8 (2%)
Abdominal mesh 
augmentation 
N = 251 (37%)
Laparoscopic 
surgery N = 228 
(91%)
Laparotomy N = 23 
(9%)
Figure 2. Surgical methods of operations for POP included in the study.  
*Native tissue repair methods are described in Appendix 2. 
 
 
